Kester Phillips, MD
Neurology · Saint Paul, MNNPI 1225357338
Payments from drug & device makers
What this record shows
Menarini Silicon Biosystems, Inc. accounts for 67.5% of it on its own, with 5 other manufacturers making up the rest. 2025 is the largest year on record at $843, more than ten times the $40 reported in 2019.
Across 12 payments — averaging $91.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Menarini Silicon Biosystems, Inc.$743
- Tempus AI, Inc$99
- Novocure Inc.$98
- Sunovion Pharmaceuticals Inc.$83
- GT Medical Technologies, Inc$55
- UCB, Inc.$23
Across 5 payments — averaging $27,810 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$139K
What the payments were for
- Consulting fees$61556%
- Food & beverage$48744%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Menarini Silicon Biosystems, Inc. | 2 | $743 |
| Tempus AI, Inc | 1 | $99 |
| Novocure Inc. | 3 | $98 |
| Sunovion Pharmaceuticals Inc. | 4 | $83 |
| GT Medical Technologies, Inc | 1 | $55 |
| UCB, Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CELLSEARCH$743
How this compares
$1,102 in reported general payments places this provider in the 70th percentile of 434 neurology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 28 | $1,067 |
| Dexamethasone | 32 | $477 |
| Levetiracetam ErLevetiracetam | 11 | $429 |
| Ondansetron Hcl | 27 | $400 |
| Methylphenidate Hcl | 12 | $209 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 13 | $83 |
| Lorazepam | 12 | $37 |
Paid to pharmacies, not to this prescriber.
Other neurology in Saint Paul
- Patricia PenovichSaint Paul$304K
- Ryan LeeSaint Paul$50K
- Gaurav GulianiSaint Paul$22K
- Jeffery AllenMinneapolis$1.1M
- Jonathan CalkwoodGolden Valley$493K
- Alejandro RabinsteinRochester$305K
- Sean PittockRochester$231K
- Irfan AltafullahGolden Valley$203K
- Jessica StulcGolden Valley$199K
- Akram DastagirGolden Valley$174K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.